Solid Biosciences Management to Host Call on April 27, 2022 to Discuss Updated Corporate Strategy and First Quarter 2022 Financial Results
Solid Biosciences (Nasdaq: SLDB) is set to release its first quarter 2022 financial results on April 27, 2022, before market opening.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Solid Biosciences (Nasdaq: SLDB) is set to release its first quarter 2022 financial results on April 27, 2022, before market opening. A conference call will follow at 8:00 a.m. ET to discuss results and updates on the SGT-001 and SGT-003 pipeline programs targeting Duchenne muscular dystrophy. The call will be accessible via a live webcast on the company’s website and through dial-in options for participants.
Positive
- Upcoming release of Q1 2022 financial results indicates transparency and engagement with investors.
- Strategic updates on SGT-001 and SGT-003 pipeline programs may enhance investor confidence.
Negative
- None.
Details
News Market Reaction – SLDB
The recorded move for SLDB in the trading session of this news was -0.31%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., April 25, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it will release first quarter 2022 financial results before the market opens on Wednesday, April 27, 2022. Management will host a conference call on the same date beginning at 8:00 a.m. ET to discuss the Company’s financial results and a strategic update to develop SGT-001 and SGT-003 pipeline programs for Duchenne.
A live webcast of the call will be available on the Company's website at www.solidbio.com under the “News & Events” tab in the Investor Relations section, or by clicking here. Participants may also access the call by dialing +1 866-763-0341 (domestic) or +1 703-871-3818 (international), referencing Conference ID# 6545417.
The archived webcast will be available in the “News and Events” section of the Company's website.
About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001, as well as our recently announced next-generation gene therapy candidate, SGT-003. For more information, please visit www.solidbio.com.
Investor Contacts:
David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com
Caitlin Lowie
Solid Biosciences
607-423-3219
clowie@solidbio.com
Media Contact:
Erich Sandoval
FINN Partners
917-497-2867
Erich.Sandoval@finnpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.